LigaChem Biosciences

LigaChem Biosciences (LCB) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Daejeon, South Korea, with over 30 years of combined expertise in drug development. Listed on KOSDAQ (141080.KQ), the company is a pioneer in next-generation Antibody-Drug Conjugate (ADC) therapeutics, leveraging its proprietary ConjuAll platform technology to overcome the limitations of conventional ADC approaches. LCB's pipeline spans ADCs targeting oncology indications, immuno-oncology small molecules, and ADC payloads. The company has built an extensive global partnership network including collaborations with Samsung Biologics, SOTIO Biotech, GO Therapeutics, Da An Biotherapeutics, and 1ST Biotherapeutics, licensing and co-developing ADC programs internationally. LigaChem Biosciences has received multiple industry accolades including two awards at the World ADC Awards, and has several programs advancing through Phase 1/2 clinical trials. With approximately 174 employees and a dedicated ADC manufacturing partnership with Samsung Biologics, LCB is accelerating the development of innovative cancer therapeutics for unmet medical needs worldwide.